trending Market Intelligence /marketintelligence/en/news-insights/trending/gwp9f_kqhhspegz1gsgwgg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Redx Pharma reaches agreement with UK regulator to resume clinical trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Redx Pharma reaches agreement with UK regulator to resume clinical trial

Redx Pharma PLC said it reached an agreement with regulators in the U.K. to resume enrollment in an early stage clinical trial of its cancer drug RXC004.

The U.K.-based pharmaceutical company expects to resume the trial during the first half of 2019, having sorted out the terms of a repurposed study with the U.K.'s Medicines and Healthcare products Regulatory Agency.

The company had to pause the phase 1/2a clinical study after the first and only patient in the trial to receive RXC004 experienced clinically significant adverse events. While the company had not elaborated on the adverse events at the time, it said it believed they were related to the drug.

Under a revised study protocol, the company will restart administering patients at a lower dose of the therapy.

RXC004 is intended to fight cancer by targeting a signaling pathway within the human body that allows tumors to avoid detection by the patient's immune system. When combined with an anti-PD1 agent, such as Bristol-Myers Squibb Co.'s Opdivo, the investigational therapy could help convert so-called cold tumors into hot tumors — allowing it to improve the effectiveness of such anti-PD1 agents.